Caixin
Caixin Global – Latest China News & Headlines

Home >

ABOUT US

CX Tech is Caixin Global's real-time tech news portal, featuring 24-hour news, short-form analysis, and roundups from business and tech media in China.

LATEST
SMIC Profits Soar to $138m in Second Quarter
Foldable Phone-Maker Plans Shenzhen IPO, Dispelling Rumors of U.S. Listing
Astra Inks Oxford Vaccine Production Deal with China’s Kangtai
Trending Story: Are Any New Graduates Really Worth 2 Million Yuan a Year? Netizens Discuss!
Trending in China: Popcorn or Cheaper Tickets - What Would Make You Return to the Cinema?
Tesla Challenger Xpeng Raises $400 Million Before Planned U.S. IPO
CATL Announces it Will Supply Batteries for Mercedes-Benz New Electric Sedan
TikTok Sees No Slowdown in Global Popularity Despite Indian Ban and U.S. Threats
Baidu Search, Sina Weibo on ‘Secret List’ of Chinese Apps Banned in India’s Latest Purge
Trending in China: Choosing a College Major - For Love or Money?
Evergrande Health Forges Ahead With Six New Electric Vehicles
Trending in China: How Cute Rabbit Ears Are On the Frontline in Fight Between Delivery Firms
Chinese Company Files Lawsuit Against Apple’s Siri for Patent Infringement Worth Billions
China Home to Six of the World’s Top 10 Unicorns, Hurun Report Says
Trending in China: Can Music Streamers Help Users’ Depression?
Core Parts of China’s Beidou Satellite System ‘100% Made in China’
Trending in China: Xiaomi CEO’s Shows How Best To Harness China’s Social Media Humor for Serious Business
Apple Takes Down Over 30,000 Apps from China Store Amid Government Crackdown
Chinese Chipmaker SMIC to Establish Joint Venture for Wafer Production
Microsoft Said Plan to Acquire TikTok Will Continue
China Adds 148 Drugs to Its National Insurance List

By Liu Denghui, Wang Lijun and Tang Ziyi / Aug 21, 2019 04:00 PM / Society & Culture

Photo: VCG

Photo: VCG

China on Tuesday added 148 drugs to a list of medicines eligible for reimbursement under government-backed insurance plans, its latest move to ease the financial burden on Chinese patients.

The updated catalog, released by the National Healthcare Security Administration, includes 47 foreign drugs and 101 traditional Chinese medicines. Notable additions involve global names such as AstraZeneca’s Kombiglyze and Merck & Co’s Janumet, both treatments for diabetes.

Five of the medicines are for rare diseases, 36 for chronic diseases such as diabetes, and 38 for pediatric use.

At the same time, the authority removed 150 drugs from the reimbursable list, ones that have relatively lower clinical value or can be substituted with better alternatives, said Xiong Xianjun, director of the Medical Service Department at the insurance administration.

Read the full report on Caixin Global later today.

Contact reporter Tang Ziyi (ziyitang@caixin.com)

Share this article
Open WeChat and scan the QR code